HEMORRHAGIC DISEASES

出血性疾病的发病机制、诊断和治疗研究进展 提出了预防疾病的建议，重点放在以下方面： 膜血小板标志物；免疫学和免疫化学研究： 血小板抗体结合的膜成分及其作用机制 药物诱导免疫中药物-抗体-血小板相互作用的研究进展 血小板减少症将在分子水平上表现出来。变量 血小板表面人类白细胞抗原-A和B标志的表达及其临床意义 将探索血小板输注疗法。 血小板的免疫紊乱.血小板输注的免疫学方面 治疗：将进行研究以提高敏感度和 血小板抗体检测的特异性和血小板的测定 相关的免疫球蛋白。先前未描述的关系， 温反应性巨球蛋白在正常的酶激活部位的特异性 血小板在自身免疫性血小板减少性紫癜发病中的作用 童年将被定义。红斑狼疮的自然病程和治疗反应 新生儿同种免疫性血小板减少性紫癜和输血后紫癜 将被进一步定性。改善血小板配型的研究 对于同种异体免疫的血小板减少患者，并确定 对血小板输注的反应中的循环免疫复合体 被引导了。 血小板分离和短期保存的最佳条件： 将寻求提高浓缩血小板质量的方法 强调腺苷环化酶抑制剂的使用，意义 激活内源性、钙激活的血小板蛋白水解酶，以及 储存过程中的搅拌方式。白细胞在人类免疫缺陷中的重要性 我们将进一步研究血小板的保存情况。 人血小板异质性：生理学意义：研究 决定人体血小板浮力密度的因素及其相互关系 浮力密度与血小板年龄的关系以及在人类中发生的变化 将在老化过程中进行血小板检测。

Studies of the pathogenesis, diagnosis and treatment of hemorrhagic diseases are proposed, with emphasis on the following areas: Membrane platelet markers; immunologic and immunochemical studies: Membrane constitutents to which platelet antibodies bind and the mechanism of drug-antibody-platelet interaction in drug-induced immune thrombocytopenia will be characterized at a molecular level. The variable expression of HLA-A and B markers on platelets and its implications for platelet transfusion therapy will be explored. Immune disorders of platelets; immunologic aspects of platelet transfusion therapy: Studies will be conducted to improve the sensitivity and specificity of platelet antibody detection and measurement of platelet associated immunoglobulins. The relationship of previously undescribed, warm-reactive macroglobulin specific for an enzyme-activated site on normal platelets to the pathogenesis of autoimmune thrombocytopenic purpura of childhood will be defined. The natural history and response to therapy of neonatal alloimmune thrombocytopenic purpura and post-transfusion purpura will be further characterized. Studies to improve matching of platelets for alloimmunized thrombocytopenic patients and to define the importance of circulating immune complexes in the response to platelet transfusions will be conducted. Optimum conditions for isolation and short-term preservation of platelets: Methods to improve the quality of platelet concentrates will be sought with emphasis on the use of inhibitors of adenylate cyclase, the significance of activation of the endogenous, calcium-activated protease of platelets, and the mode of agitation during storage. The importance of leukocytes in platelet preservation will be further characterized. Human platelet heterogeneity: physiologic significance: Studies of the factors that determine buoyant density of human platelets, the relationship of buoyant density to platelet age, and the changes that occur in human platelets during the aging process will be conducted.